Wang Yi, Xiao Zhi-jian, Liu Peng, Yang Chen, Yang Ren-chi, Cai Ying-lin, Han Zhong-chao
Institute of Hematology, CAMS and PUMC, Tianjin 300020, China.
Zhonghua Xue Ye Xue Za Zhi. 2003 May;24(5):249-52.
To evaluate the expression of vascular endothelial growth factor (VEGF) and its receptors KDR and Flt1 in patients with acute myeloid leukemia (AML).
The expression of VEGF and its receptors mRNA was assayed by RT-PCR, the plasma of VEGF by ELISA.
In 13 AML cell lines, the expression of VEGF, KDR and Flt1 mRNA were found in 13 (100%), 7 (53.8%) and 12 (92.3%), respectively. There were 21 (65.6%), 1 (3.1%), and 17 (53.1%) of 31 (AML) patients bone marrow mononuclear cells (BMMNCs) expressing VEGF, KDR and Flt1 mRNA, respectively. None of BMMNCs from 3 normal donor and CD(34)(+) cells from 2 normal donor was found to express VEGF, KDR and Flt1 mRNA. The plasma level of VEGF of 39 patients (new diagnosed, relapsed and secondary-AML) before treatment was (135.3 +/- 87.9) ng/L which was significantly higher than that of 15 complete remission (CR) patients (80.6 +/- 36.9) ng/L and 12 normal donors (80.6 +/- 33.1) micro g/L (P = 0.028, 0.007). The plasma level of VEGF of 15 non-responsive patients was (188.2 +/- 118.6) ng/L after two cycles of chemotherapy which was higher than that of 20 CR patients [(104.2 +/- 30.9) ng/L] (P = 0.004).
VEGF and its receptors KDR and Flt1 mRNAs were expressed in BMMNCs of AML patients. The plasma level of VEGF directly affected the response to chemotherapy in AML patients.
评估血管内皮生长因子（VEGF）及其受体KDR和Flt1在急性髓系白血病（AML）患者中的表达。
采用逆转录聚合酶链反应（RT-PCR）检测VEGF及其受体mRNA的表达，采用酶联免疫吸附测定（ELISA）检测血浆VEGF水平。
在13株AML细胞系中，VEGF、KDR和Flt1 mRNA的表达阳性率分别为100%（13/13）、53.8%（7/13）和92.3%（12/13）。31例AML患者骨髓单个核细胞（BMMNCs）中，VEGF、KDR和Flt1 mRNA的表达阳性率分别为65.6%（21/31）、3.1%（1/31）和53.1%（17/31）。3例正常供者的BMMNCs及2例正常供者的CD(34)(+)细胞均未检测到VEGF、KDR和Flt1 mRNA表达。39例初诊、复发及继发性AML患者治疗前血浆VEGF水平为（135.3±87.9）ng/L，显著高于15例完全缓解（CR）患者的（80.6±36.9）ng/L及12例正常供者的（80.6±33.1）μg/L（P = 0.028，0.007）。15例化疗无效患者化疗两个周期后血浆VEGF水平为（188.2±118.6）ng/L，高于20例CR患者的[（104.2±30.9）ng/L]（P = 0.004）。
AML患者BMMNCs中存在VEGF及其受体KDR和Flt1 mRNA的表达。血浆VEGF水平直接影响AML患者对化疗的反应。
